Heading back to the trough (levels of biologics in IBD)
- PMID: 25311382
- DOI: 10.1016/j.cgh.2014.10.007
Heading back to the trough (levels of biologics in IBD)
Comment in
-
It Is Time to Treat to Trough: Staying Ahead of the Curve in Biologic Testing.Clin Gastroenterol Hepatol. 2015 Dec;13(13):2384. doi: 10.1016/j.cgh.2015.03.031. Epub 2015 Apr 8. Clin Gastroenterol Hepatol. 2015. PMID: 25862986 No abstract available.
-
Reply: To PMID 25311382.Clin Gastroenterol Hepatol. 2015 Dec;13(13):2384-5. doi: 10.1016/j.cgh.2015.07.028. Epub 2015 Jul 26. Clin Gastroenterol Hepatol. 2015. PMID: 26215841 No abstract available.
Similar articles
-
It Is Time to Treat to Trough: Staying Ahead of the Curve in Biologic Testing.Clin Gastroenterol Hepatol. 2015 Dec;13(13):2384. doi: 10.1016/j.cgh.2015.03.031. Epub 2015 Apr 8. Clin Gastroenterol Hepatol. 2015. PMID: 25862986 No abstract available.
-
Reply: To PMID 25311382.Clin Gastroenterol Hepatol. 2015 Dec;13(13):2384-5. doi: 10.1016/j.cgh.2015.07.028. Epub 2015 Jul 26. Clin Gastroenterol Hepatol. 2015. PMID: 26215841 No abstract available.
-
Medical Therapy for Inflammatory Bowel Disease.Surg Clin North Am. 2015 Dec;95(6):1159-82, vi. doi: 10.1016/j.suc.2015.08.004. Epub 2015 Oct 23. Surg Clin North Am. 2015. PMID: 26596920 Review.
-
Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders.Clin Gastroenterol Hepatol. 2018 Sep;16(9):1374-1384. doi: 10.1016/j.cgh.2018.02.024. Epub 2018 Mar 2. Clin Gastroenterol Hepatol. 2018. PMID: 29481970 Review.
-
Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis.Clin Gastroenterol Hepatol. 2017 Sep;15(9):1359-1372.e6. doi: 10.1016/j.cgh.2017.02.005. Epub 2017 Feb 14. Clin Gastroenterol Hepatol. 2017. PMID: 28232073 Review.
Cited by
-
Biologics: how far can they go in Crohn's disease?Gastroenterol Rep (Oxf). 2022 Sep 29;10:goac049. doi: 10.1093/gastro/goac049. eCollection 2022. Gastroenterol Rep (Oxf). 2022. PMID: 36196255 Free PMC article. Review.
-
How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?World J Gastroenterol. 2015 Oct 28;21(40):11331-42. doi: 10.3748/wjg.v21.i40.11331. World J Gastroenterol. 2015. PMID: 26525434 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources